Patents Assigned to Supernus Pharmaceuticals, Inc.
  • FORMULATIONS OF VILOXAZINE
    Publication number: 20130202661
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 8, 2013
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventor: Supernus Pharmaceuticals, Inc.
  • Once daily formulations of tetracyclines
    Patent number: 8470364
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: June 25, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • ONCE DAILY TROSPIUM CHLORIDE TREATMENT METHOD
    Publication number: 20130089607
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: September 19, 2012
    Publication date: April 11, 2013
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventor: SUPERNUS PHARMACEUTICALS, INC.
  • Once daily formulations of tetracyclines
    Patent number: 8394406
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: March 12, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Once daily formulations of tetracyclines
    Patent number: 8394405
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: March 12, 2013
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Sustained-release formulations of topiramate
    Patent number: 8298580
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: October 30, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
  • Sustained-release formulations of topiramate
    Patent number: 8298576
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: October 30, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent number: 8211464
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: July 3, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Once daily formulations of tetracyclines
    Patent number: 8206740
    Abstract: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: June 26, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Arash Raoufinia, Niraj Shah
  • Controlled release compositions of gamma-hydroxybutyrate
    Patent number: 8193211
    Abstract: The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: June 5, 2012
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Niraj Shah, Padmanabh P. Bhatt, Scott Ibrahim
  • METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF
    Publication number: 20110251198
    Abstract: Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.
    Type: Application
    Filed: April 12, 2011
    Publication date: October 13, 2011
    Applicant: Supernus Pharmaceuticals Inc.
    Inventors: Likan Liang, Padmanabh P. Bhatt, David Dain, Jean-Philippe Taquet, Aleksandr Pechenov, Alexei Tchesnokov, Reynold Mariaux
  • Modified release preparations containing oxcarbazepine and derivatives thereof
    Patent number: 8017149
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: September 13, 2011
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
    Patent number: 7910128
    Abstract: Disclosed are pharmaceutical compositions, particularly oral dosage forms, which comprise two or more enteric coating materials, either as a coating or as part of a matrix dosage form, and methods of making and using the same. The compositions are characterized by having a sustained release profile at lower pH and an accelerated dissolution profile at higher pH.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: March 22, 2011
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Rong-Kun Chang, Niraj Shah
  • Method of treating seizures using modified release formulations of oxcarbazepine
    Patent number: 7910131
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 22, 2011
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • PHARMACEUTICAL COMPOSITION FOR ONCE A DAY ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221356
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR THE ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221352
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221354
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Pharmaceutical Composition Comprising Trospium Chloride for Once-A-Day Administration
    Publication number: 20100222375
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • Pharmaceutical Composition For Once-A-Day Administration of Trospium Chloride
    Publication number: 20100221353
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw KIDANE, Henry H. Flanner, Padmanabh Bhatt, Arash Raoufinia
  • PHARMACEUTICAL COMPOSITION FOR ONCE-A-DAY ORAL ADMINISTRATION OF TROSPIUM CHLORIDE
    Publication number: 20100221355
    Abstract: A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: SUPERNUS PHARMACEUTICALS, INC.
    Inventors: Argaw KIDANE, Henry H. FLANNER, Padmanabh BHATT, Arash RAOUFINIA